Twist Bioscience (TWST) Corporate presentation summary

Strategic positioning and market overview

• Proprietary silicon-based DNA synthesis platform supports diverse applications in therapeutics, diagnostics, industrial, research, agriculture, and applied markets, with a global footprint and capacity for growth.

• Over 3,800 customers, including leading diagnostics, pharma, biotech companies, and top universities, rely on solutions that accelerate discovery and reduce risk.

• Multi-billion dollar markets targeted, with a blended market growth rate of 11–14% and a serviceable addressable market (SAM) projected to exceed $7B by 2030.

Product innovation and operational excellence

• Continuous platform improvements have reduced costs by ~60%, waste by ~70%, and turnaround time by ~73%, while quadrupling capacity since 2023.

• Automation initiatives have doubled throughput in 20% of the previous physical footprint, increasing productivity and reducing required headcount.

• Integrated, automated systems enable scalable, efficient workflows for DNA synthesis, NGS panels, and protein solutions.

Financial performance and growth

• FY2025 revenue reached ~$377M, with FY2026 guidance of $442–$447M and gross margin exceeding 50% in the second half of FY2025.

• 13 consecutive quarters of sequential revenue growth, with a 33% CAGR over six years and significant margin improvement.

• Adjusted EBITDA loss narrowed to $(46.9)M in FY2026 guidance, with breakeven targeted for Q4 FY2026.